Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas

Endocrine-Related Cancer

Volumn 18, Issue 1, 2011, Pages 51-59

  Hentic, O ^a   Couvelard, A ^a   Rebours, V ^a   Zappa, M ^a   Dokmak, S ^a   Hammel, P ^a   Maire, F ^a   O'Toole, D ^a   Levy P ^a   Sauvanet, A ^a   Ruszniewski, P ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; ENDOCRINE TUMOR; FEMALE; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL TUMOR; HUMAN; INDEPENDENT VARIABLE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS TUMOR; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PROGNOSIS; RECTUM TUMOR; RETROSPECTIVE STUDY; SMALL INTESTINE TUMOR; STOMACH TUMOR; SURVIVAL RATE; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DIGESTIVE SYSTEM NEOPLASMS; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 79251521512     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0319     Document Type: Article

References (41)

1. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A & Falconi M 2008 Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Annals of Oncology 19 903-938. (doi:10.1093/annonc/mdm552)
2. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY & Bentrem DJ 2008 Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Annals of Surgery 247 490-500. (doi:10.1097/SLA.0b013e31815b9cae)
3. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y & Blumgart LH 2000 Hepatic neuroendocrine metastases: does intervention alter outcomes? Journal of the American College of Surgeons 190 432-445. (doi:10.1016/S1072-7515(00)00222-2)
4. Clarke MR, Baker EE, Weyant RJ, Hill L & Carty SE 1997 Proliferative activity in pancreatic endocrine tumors: association with function, metastases, and survival. Endocrine Pathology 8 181-187. (doi:10.1007/BF02738784)
5. Couvelard A, Hu J, Steers G, O'Toole D, Sauvanet A, Belghiti J, Bedossa P, Gatter K, Ruszniewski P & Pezzella F 2006 Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors. Gastroenterology 131 1597-1610. (doi:10.1053/j.gastro.2006.09.007) (Pubitemid 44780863)
6. Couvelard A, Deschamps L, Ravaud P, Baron G, Sauvanet A, Hentic O, Colnot N, Paradis V, Belghiti J, Bedossa P et al. 2009 Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Modern Pathology 22 273-281. (doi:10.1038/ modpathol.2008.177)
7. Dominguez S, Denys A, Menu Y & Ruszniewski P 1999 Hepaticarterial chemoembolization in the management of advanced digestive endocrine tumours. Italian Journal of Gastroenterology and Hepatology 31 (Supplement 2) S213-S215.
8. Dominguez S, Denys A, Madeira I, Hammel P, Vilgrain V, Menu Y, Bernades P & Ruszniewski P 2000 Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. European Journal of Gastroenterology & Hepatology 12 151-157. (doi:10.1097/00042737-200012020- 00004)
9. Ducreux MP, Boige V, Leboulleux S, Malka D, Kergoat P, Dromain C, Elias D, de Baere T, Sabourin JC, Duvillard P et al. 2006A phase II study of irinotecanwith 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas. Oncology 70 134-140. (doi:10.1159/000093004)
10. Durante C, Boukheris H, Dromain C, Duvillard P, Leboulleux S, Elias D, de Baere T, Malka D, Lumbroso J, Guigay J et al. 2009 Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocrine-Related Cancer 16 585-597. (doi:10.1677/ERC-08-0301)
11. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, Schlumberger M, Pocard M, Boige V, Miquel C et al. 2003 Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 133 375-382. (doi:10.1067/msy.2003.114) (Pubitemid 36515325)
12. Eriksson B, Kloppel G, Krenning E, Ahlman H, Plockinger U, Wiedenmann B, Arnold R, Auernhammer C, Korner M, Rindi G et al. 2008 Consensus guidelines for the management of patients with digestive neuroendocrine tumors - well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87 8-19. (doi:10.1159/000111034)
13. Faggiano A, Mansueto G, Ferolla P, Milone F, del Basso de Caro ML, Lombardi G, Colao A & De Rosa G 2008 Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors. Journal of Endocrinological Investigation 31 216-223.
14. Gentil Perret A, Mosnier JF, Buono JP, Berthelot P, Chipponi J, Balique JG, Cuilleret J, Dechelotte P & Boucheron S 1998 The relationship between MIB-1proliferation index and outcome in pancreatic neuroendocrine tumors. American Journal of Clinical Pathology 109 286-293. (Pubitemid 28110570)
15. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF & Klimstra DS 2002 Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. Journal of Clinical Oncology 20 2633-2642. (doi:10.1200/JCO.2002.10.030)
16. Kianmanesh R, Sauvanet A, Hentic O, Couvelard A, Levy P, Vilgrain V, Ruszniewski P & Belghiti J 2008 Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Annals of Surgery 247 659-665. (doi:10.1097/SLA.0b013e31816a7061)
17. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, Vilgrain V, Belghiti J, Bernades P & Ruszniewski P 1998 Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43 422-427. (doi:10.1136/gut.43.3.422)
18. Maire F, Hammel P, Faivre S, Hentic O, Yapur L, Larroque B, Couvelard A, Zappa M, Raymond E, Levy P et al. 2009 Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. Neuroendocrinology 90 67-72. (doi:10.1159/000225389)
19. Marrache F, Vullierme MP, Roy C, El Assoued Y, Couvelard A, O'Toole D, Mitry E, Hentic O, Hammel P, Levy P et al. 2007 Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. British Journal of Cancer 96 49-55. (doi:10.1038/sj.bjc.6603526)
20. Mitry E & Rougier P 2001 The treatment of undifferentiated neuroendocrine tumors. Critical Reviews in Oncology/Hematology 37 47-51. (doi:10.1016/S1040-8428(00)00073-1)
21. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M et al. 1999 Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. British Journal of Cancer 81 1351-1355. (doi:10.1038/sj.bjc.6690325)
22. Modlin IM, Lye KD & Kidd M 2003 A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 934-959. (doi:10.1002/cncr.11105)
23. Moertel CG & Hanley JA 1979 Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clinical Trials 2 327-334.
24. Moertel CG, Kvols LK, O'Connell MJ & Rubin J 1991 Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68 227-232. (doi:10.1002/1097-0142(19910715)68:2〈227::AID- CNCR2820680202〉3.0.CO;2-I)
25. Moertel CG, Johnson CM, McKusick MA, Martin JK, Nagorney DM, Kvols LK, Rubin J & Kunselman S 1994 The management of patients with advanced carcinoid tumors and islet cell carcinomas. Annals of Internal Medicine 120 302-309.
26. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, Di Fonzo M, Tornatore V, Milione M, Angeletti S et al. 2005 Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocrine-Related Cancer 12 1083-1092. (doi:10.1677/erc.1.01017)
27. Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Rocken C, Rindi G & Wiedenmann B 2008a Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113 256-265. (doi:10.1002/cncr.23549)
28. Pape UF, Babouri A, Couvelard A, Jann H, Müller-Nordhorn J, Hentic-Dhome O, Pavel M, Hammel P, Wiedenmann B & Ruszniewski P 2008b Validation of the new TNM classification of neuroendocrine tumours of mid and hindgut origin. Gastroenterol Clin Biol 33 (Supplement 1) A254. (doi:10.1016/S0399-8320(09)73102-1)
29. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, Iacono C, Serio G & Zamboni G 1996 Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Human Pathology 27 1124-1134. (doi:10.1016/S0046- 8177(96)90303-2)
30. Rindi G & Bordi C 2003 Highlights of the biology of endocrine tumours of the gut and pancreas. Endocrine-Related Cancer 10 427-436. (doi:10.1677/erc.0.0100427)
31. Rindi G & Bordi C 2005 Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics. Best Practice & Research. Clinical Gastroenterology 19 519-534. (doi:10.1016/j.bpg.2005.03.005)
32. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P et al. 2006 TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archive 449 395-401. (doi:10.1007/s00428-006-0250-1)
33. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A et al. 2007 TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archive 451 757-762. (doi:10.1007/s00428-007-0452-1)
34. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadeti B, Pape UF, Bläker M et al. 2009 Placebo-controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. Journal of Clinical Oncology 28 4656-4663. (doi:10.1200/JCO.2009.22.8510)
35. Skinazi F, Zins M, Menu Y, Bernades P & Ruszniewski P 1996 Liver metastases of digestive endocrine tumours: natural history and response to medical treatment. European Journal of Gastroenterology & Hepatology 8 673-678.
36. Solcia E, Rindi G, Paolotti D, Luinetti O, Klersy C, Zangrandi A, La Rosa S & Capella C 1998 Natural history, clinicopathologic classification and prognosis of gastric ECL cell tumors. Yale Journal of Biology and Medicine 71 285-290.
37. Solcia E, Kloppel G & Sobin LH 2000 Histological typing of endocrine tumours. In World Health Organization International Histological Classification of Tumours, 2nd edn, pp 61-68. Berlin: Springer.
38. Steinmuller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J et al. 2008 Consensus guidelines for the management of patients with liver metastases from digestive (neuro)- endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87 47-62. (doi:10.1159/000111037)
39. Strosberg J, Nasir A, Coppola D, Wick M & Kvols L 2009b Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Human Pathology 40 1262-1268. (doi:10.1016/j.humpath.2009.01.010)
40. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 92 205-216. (doi:10.1093/jnci/92.3.205)
41. Van Gompel JJ, Sippel RS, Warner TF & Chen H 2004 Gastrointestinal carcinoid tumors: factors that predict outcome. World Journal of Surgery 28 387-392. (doi:10.1007/s00268-003-7019-3)